Pharmacoeconomic considerations in the treatment of psoriatic arthritis

Rheumatology

Volumn 45, Issue 7, 2006, Pages 790-791

  Kavanaugh, Arthur ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; ENTHESITIS; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; JOINT DESTRUCTION; JOINT RADIOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745631790     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel153     Document Type: Editorial

References (18)

1. Kavanaugh A, Cohen S, Cush J. The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol 2004;31:1881-4.
2. Mease PJ, Antoni CE. Psoriatic arthritis treatment: Biological response modifiers. Ann Rheum Dis 2005;64(Suppl. II):iI78-82.
3. Antoni C, Krueger G, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
4. Kavanaugh A. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Rheum Dis Clin N Amer 2006;32:45-56.
5. Sokka T, Krishnan E, Hakkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003;48:59-63.
6. Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: A prevalence based study. Arthritis Rheum (Arthritis Care Res) 2003;49:64-70.
7. Wong J. Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 2005;22(Suppl. 35):S65-70.
8. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatol 2004;43:4-6.
9. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-54.
10. Smolen J, Han C, van der Heijde D et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
11. Bansback NJ, Ara R, Barkham N et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology.
12. Rahman P, Nguyen E, Cheung C, Schentag C, Gladman D. Comparison of radiologic severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28:1041-4.
13. Pisu M, James N, Sampsel S, Saag K. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology 2005;44:781-8.
14. Verstappen SMM, Bijlsma JWJ, Verkleij H et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum (Arthritis Care Res) 2004;51:488-97.
15. Cooper NJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology 2000;39:28-33.
16. Kavanaugh A, Krueger G, Yan S et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. Arthritis Rheum 2004;50(Suppl):S318.
17. Kobelt G, Sandlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab. Rheumatology 2004;43:1158-66.
18. Boonen A, van der Heijde D, Severens J et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006;65:201-8.